DK1621198T3 - Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister - Google Patents

Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister

Info

Publication number: DK1621198T3
Authority: DK; Denmark
Prior art keywords: receptor subtype; ht1a receptor; carbostyril derivatives; subtype agonists; substituted carbostyril
Prior art date: 2001-01-29

Application number

DK05023971T

Other languages

English (en)

Inventor

Yasufumi Uwahodo

Shaun Jordan

Tetsuro Kikuchi

Katsura Tottori

Tsuyoshi Hirose

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-29

Filing date

2002-01-29

Publication date

2007-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1621198(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-01-29 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2007-09-24 Application granted granted Critical

2007-09-24 Publication of DK1621198T3 publication Critical patent/DK1621198T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Psychology (AREA)
Obesity (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK05023971T 2001-01-29 2002-01-29 Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister DK1621198T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77021001A	2001-01-29	2001-01-29
PCT/JP2002/000626 WO2002060423A2 (en)	2001-01-29	2002-01-29	Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists

Publications (1)

Publication Number	Publication Date
DK1621198T3 true DK1621198T3 (da)	2007-09-24

Family

ID=25087808

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK06015782.3T DK1712225T3 (da)	2001-01-29	2002-01-29	Substituered carbostyril-derivater som agonister af receptorundertype 5-HT 1A til behandling af bipolar lidelse
DK02716434T DK1355639T3 (da)	2001-01-29	2002-01-29	Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister
DK05023971T DK1621198T3 (da)	2001-01-29	2002-01-29	Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK06015782.3T DK1712225T3 (da)	2001-01-29	2002-01-29	Substituered carbostyril-derivater som agonister af receptorundertype 5-HT 1A til behandling af bipolar lidelse
DK02716434T DK1355639T3 (da)	2001-01-29	2002-01-29	Substituerede carbostyrilderivater som 5-HT1A-receptorsubtypeagonister

Country Status (19)

Country	Link
EP (3)	EP1355639B1 (da)
JP (4)	JP4178032B2 (da)
KR (5)	KR100763288B1 (da)
CN (3)	CN1879624A (da)
AR (4)	AR032641A1 (da)
AT (3)	ATE322894T1 (da)
AU (4)	AU2002226752C1 (da)
BR (1)	BR0206237A (da)
CA (2)	CA2429496C (da)
CY (3)	CY1105631T1 (da)
DE (3)	DE60210581T2 (da)
DK (3)	DK1712225T3 (da)
ES (3)	ES2286755T3 (da)
MX (2)	MXPA03006603A (da)
MY (1)	MY129355A (da)
PH (1)	PH12014500937A1 (da)
PT (3)	PT1355639E (da)
TW (2)	TWI302832B (da)
WO (1)	WO2002060423A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en)	2001-09-25	2014-04-22	Otsuka Pharmaceutical Co., Ltd.	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DE10148233A1 (de) *	2001-09-28	2003-04-10	Boehringer Ingelheim Pharma	Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
CA2529857A1 (en) *	2002-07-30	2004-02-05	Peter Migaly	Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
DE60317098T2 (de) *	2002-12-27	2008-08-07	Otsuka Pharmaceutical Co., Ltd.	Carbostyril-derivate mit selektiven serotonin-aufnahmeinhibitoren zur behandlung von gemütskrankheiten
AR042806A1 (es)	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CN102000336A (zh) *	2003-05-23	2011-04-06	大塚制药株式会社	用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) *	2004-01-30	2008-06-13	Biocortech	Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
US8227476B2 (en) *	2005-08-03	2012-07-24	Sprout Pharmaceuticals, Inc.	Use of flibanserin in the treatment of obesity
TW200848041A (en)	2007-03-30	2008-12-16	Otsuka Pharma Co Ltd	A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en)	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) *	2008-05-30	2009-12-10	Otsuka Pharmaceut Co Ltd	アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en)	2009-12-22	2011-06-29	Gmeiner, Peter	New aminotetraline derivatives
AR090245A1 (es)	2012-03-06	2014-10-29	Otsuka Pharma Co Ltd	Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54130587A (en) *	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
JPS5646812A (en) *	1979-09-27	1981-04-28	Otsuka Pharmaceut Co Ltd	Central nervous system depressant
US4764416A (en) *	1986-07-01	1988-08-16	Mitsubishi Denki Kabushiki Kaisha	Electric element circuit using oxidation-reduction substances
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
WO1992020655A1 (en) *	1991-05-20	1992-11-26	The Upjohn Company	Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) *	1991-12-26	1996-07-02	Yoshitomi Pharmaceutical Industries, Ltd.	Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) *	1992-10-23	1994-05-24	New York University	Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) *	1992-12-09	1992-12-09	Lundbeck & Co As H	Forbindelser
JP2959615B2 (ja) *	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) *	1996-02-27	1997-11-11	Yoshitomi Pharmaceut Ind Ltd	縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) *	1996-04-23	1997-11-18	Neurogen Corporation	Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
AU730856C (en) *	1996-05-07	2001-11-15	Pfizer Inc.	Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
JP4012994B2 (ja) *	1996-05-08	2007-11-28	大塚製薬株式会社	抗不安薬
DE69719765T2 (de) *	1996-08-27	2003-10-16	Wyeth, Madison	4-aminoethoxy-indolderivate als dopamin d2 agonisten und als 5ht1a liganden
CA2317515A1 (en) *	1998-02-03	1999-08-05	Frances Christy Nelson	Oxazole derivatives as serotonin-1a receptor agonists
EP1073636A1 (en) *	1998-04-13	2001-02-07	American Home Products Corporation	4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) *	1998-05-25	1999-12-07	Mitsui Chem Inc	ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
PT1397145E (pt) *	2001-06-19	2006-10-31	Norbert Muller	Utilizacao de inibidores da cox-2 para o tratamento de esquizofrenia ou de disturbios de tiques
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

2002
- 2002-01-15 AR ARP020100118A patent/AR032641A1/es not_active Application Discontinuation
- 2002-01-25 TW TW091101289A patent/TWI302832B/zh not_active IP Right Cessation
- 2002-01-25 TW TW093127321A patent/TWI331919B/zh not_active IP Right Cessation
- 2002-01-26 MY MYPI20020297A patent/MY129355A/en unknown
- 2002-01-29 AT AT02716434T patent/ATE322894T1/de active
- 2002-01-29 PT PT02716434T patent/PT1355639E/pt unknown
- 2002-01-29 CN CNA2006100943881A patent/CN1879624A/zh active Pending
- 2002-01-29 PT PT05023971T patent/PT1621198E/pt unknown
- 2002-01-29 DE DE60210581T patent/DE60210581T2/de not_active Expired - Lifetime
- 2002-01-29 ES ES05023971T patent/ES2286755T3/es not_active Expired - Lifetime
- 2002-01-29 KR KR1020067005164A patent/KR100763288B1/ko not_active Ceased
- 2002-01-29 PT PT06015782T patent/PT1712225E/pt unknown
- 2002-01-29 AU AU2002226752A patent/AU2002226752C1/en not_active Expired
- 2002-01-29 CN CNB2005100228288A patent/CN100450485C/zh not_active Expired - Lifetime
- 2002-01-29 DK DK06015782.3T patent/DK1712225T3/da active
- 2002-01-29 WO PCT/JP2002/000626 patent/WO2002060423A2/en not_active Ceased
- 2002-01-29 EP EP02716434A patent/EP1355639B1/en not_active Expired - Lifetime
- 2002-01-29 BR BR0206237-2A patent/BR0206237A/pt not_active Application Discontinuation
- 2002-01-29 MX MXPA03006603A patent/MXPA03006603A/es active IP Right Grant
- 2002-01-29 EP EP06015782A patent/EP1712225B1/en not_active Revoked
- 2002-01-29 DK DK02716434T patent/DK1355639T3/da active
- 2002-01-29 DK DK05023971T patent/DK1621198T3/da active
- 2002-01-29 DE DE60239711T patent/DE60239711D1/de not_active Expired - Lifetime
- 2002-01-29 ES ES02716434T patent/ES2261652T3/es not_active Expired - Lifetime
- 2002-01-29 CA CA2429496A patent/CA2429496C/en not_active Expired - Lifetime
- 2002-01-29 CN CNB028035518A patent/CN1239154C/zh not_active Expired - Lifetime
- 2002-01-29 KR KR1020037008565A patent/KR100601073B1/ko not_active Expired - Lifetime
- 2002-01-29 ES ES06015782T patent/ES2363366T3/es not_active Expired - Lifetime
- 2002-01-29 AT AT05023971T patent/ATE362763T1/de active
- 2002-01-29 KR KR1020077010561A patent/KR100825705B1/ko not_active Expired - Lifetime
- 2002-01-29 DE DE60220325T patent/DE60220325T2/de not_active Expired - Lifetime
- 2002-01-29 KR KR1020057019896A patent/KR100653591B1/ko not_active Expired - Lifetime
- 2002-01-29 CA CA2700314A patent/CA2700314C/en not_active Expired - Lifetime
- 2002-01-29 JP JP2002560616A patent/JP4178032B2/ja not_active Expired - Lifetime
- 2002-01-29 MX MX2011010975A patent/MX344556B/es unknown
- 2002-01-29 KR KR1020067014046A patent/KR100713607B1/ko not_active Expired - Lifetime
- 2002-01-29 AT AT06015782T patent/ATE504293T1/de active
- 2002-01-29 EP EP05023971A patent/EP1621198B1/en not_active Revoked
2005
- 2005-04-27 AU AU2005201772A patent/AU2005201772C1/en not_active Expired
2006
- 2006-06-28 CY CY20061100884T patent/CY1105631T1/el unknown
2007
- 2007-04-17 AU AU2007201701A patent/AU2007201701B2/en not_active Expired
- 2007-07-09 JP JP2007179275A patent/JP4896831B2/ja not_active Expired - Lifetime
- 2007-08-20 CY CY20071101093T patent/CY1108031T1/el unknown
2009
- 2009-10-29 AU AU2009233591A patent/AU2009233591B2/en not_active Expired
2010
- 2010-12-28 AR ARP100104973A patent/AR079761A2/es not_active Application Discontinuation
2011
- 2011-04-08 AR ARP110101189A patent/AR080849A2/es not_active Application Discontinuation
- 2011-04-18 CY CY20111100391T patent/CY1111392T1/el unknown
- 2011-06-15 JP JP2011133032A patent/JP5683010B2/ja not_active Expired - Lifetime
- 2011-06-15 JP JP2011133033A patent/JP2011184460A/ja active Pending
2014
- 2014-04-28 PH PH12014500937A patent/PH12014500937A1/en unknown
2015
- 2015-03-13 AR ARP150100766A patent/AR099754A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN100450485C (zh)	2009-01-14
JP5683010B2 (ja)	2015-03-11
JP4896831B2 (ja)	2012-03-14
KR100653591B1 (ko)	2006-12-05
WO2002060423A3 (en)	2003-04-10
DE60220325D1 (de)	2007-07-05
TWI331919B (en)	2010-10-21
MXPA03006603A (es)	2004-02-12
WO2002060423A2 (en)	2002-08-08
EP1355639B1 (en)	2006-04-12
KR100601073B1 (ko)	2006-07-19
DE60239711D1 (de)	2011-05-19
KR20070065425A (ko)	2007-06-22
KR20050107822A (ko)	2005-11-15
ES2286755T3 (es)	2007-12-01
DE60210581T2 (de)	2007-04-05
KR100713607B1 (ko)	2007-05-02
CN1484524A (zh)	2004-03-24
DE60220325T2 (de)	2008-01-17
KR20030065570A (ko)	2003-08-06
JP2004517937A (ja)	2004-06-17
JP2007297405A (ja)	2007-11-15
AU2007201701B2 (en)	2010-06-17
CA2700314A1 (en)	2002-08-08
MX344556B (es)	2016-12-20
EP1621198A3 (en)	2006-04-12
CY1111392T1 (el)	2015-08-05
AU2005201772C1 (en)	2010-06-03
JP4178032B2 (ja)	2008-11-12
ES2261652T3 (es)	2006-11-16
JP2011184460A (ja)	2011-09-22
DK1712225T3 (da)	2011-06-20
AR099754A2 (es)	2016-08-17
CN1239154C (zh)	2006-02-01
DK1355639T3 (da)	2006-08-14
PT1621198E (pt)	2007-06-08
PT1712225E (pt)	2011-04-18
TW200522960A (en)	2005-07-16
AU2009233591A1 (en)	2009-11-19
AR079761A2 (es)	2012-02-15
AU2009233591B2 (en)	2011-10-20
AU2002226752C1 (en)	2010-02-18
EP1712225B1 (en)	2011-04-06
AR080849A2 (es)	2012-05-09
EP1355639A2 (en)	2003-10-29
EP1712225A1 (en)	2006-10-18
KR20060085260A (ko)	2006-07-26
AU2007201701A1 (en)	2007-05-10
CN1879624A (zh)	2006-12-20
CY1105631T1 (el)	2010-12-22
ATE504293T1 (de)	2011-04-15
CA2700314C (en)	2012-04-24
BR0206237A (pt)	2003-12-23
MY129355A (en)	2007-03-30
KR20060028485A (ko)	2006-03-29
PH12014500937A1 (en)	2015-09-21
HK1061805A1 (en)	2004-10-08
TWI302832B (en)	2008-11-11
AR032641A1 (es)	2003-11-19
EP1621198A2 (en)	2006-02-01
AU2002226752B2 (en)	2005-03-17
AU2005201772A1 (en)	2005-05-19
CY1108031T1 (el)	2013-09-04
KR100763288B1 (ko)	2007-10-04
DE60210581D1 (en)	2006-05-24
HK1091403A1 (zh)	2007-01-19
ATE362763T1 (de)	2007-06-15
CN1813745A (zh)	2006-08-09
KR100825705B1 (ko)	2008-04-29
CA2429496A1 (en)	2002-08-08
AU2005201772B2 (en)	2007-05-17
PT1355639E (pt)	2006-06-30
ATE322894T1 (de)	2006-04-15
CA2429496C (en)	2010-10-19
JP2011225587A (ja)	2011-11-10
ES2363366T3 (es)	2011-08-02
EP1621198B1 (en)	2007-05-23

Publication	Publication Date	Title
DK1621198T3 (da)	2007-09-24	Substituerede carbostyrilderivater som 5-HT1A-receptorsubtype-agonister
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
DK1385825T3 (da)	2007-11-05	Substituerede 2-pyridincyclohexan-1,4-diaminderivater
NO20044654L (no)	2004-10-28	Piperidinoylpiperidiner som 5-HTIF-agonister
DK1309559T3 (da)	2006-10-02	4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
PL370408A1 (en)	2005-05-30	New sulfonamide derivatives as d3-receptor agonists
LTPA2014013I1 (lt)	2014-04-25	Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
NO20040465L (no)	2004-02-02	N-fenylpyrrolguanidin-derivater som melanokortin-mottagerligander
DE60225563D1 (de)	2008-04-24	4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DK1049689T3 (da)	2002-07-22	4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
DK1317442T3 (da)	2006-02-13	Quinolinonderivater som tyrosinkinaseinhibitorer
NO20041235L (no)	2004-03-24	Kinolinderivater som neuropeptid Y antagonister
NO20043022L (no)	2004-07-15	5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
ATE377419T1 (de)	2007-11-15	Substituierte 4-alkoxyoxazol derivate als ppar agonisten
DK1735304T3 (da)	2009-04-20	Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
NO20021459D0 (no)	2002-03-22	Piperazin-derivater som 5-HT1B-antagonister
NO20052797D0 (no)	2005-06-09	Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister
NO20032142D0 (no)	2003-05-13	Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
DK1305319T3 (da)	2006-08-14	4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
ATE492535T1 (de)	2011-01-15	4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
DK1560828T3 (da)	2006-09-04	Imidazoquinolinderivater som adenosin-A3-receptorligander
NO20043119L (no)	2004-07-20	Triazolokinolinderivater som kan anvendes som adenosinreseptorligander
DE60214408D1 (de)	2006-10-12	5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
DE60210058D1 (de)	2006-05-11	Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
DK1406888T3 (da)	2006-09-18	Substituerede gamma-lactonforbindelser som NMDA-antagonister